1
|
Friedman S, Xu H, Harwood JM, Azocar F, Hurley B, Ettner SL. The Mental Health Parity and Addiction Equity Act evaluation study: Impact on specialty behavioral healthcare utilization and spending among enrollees with substance use disorders. J Subst Abuse Treat 2017; 80:67-78. [PMID: 28755776 DOI: 10.1016/j.jsat.2017.06.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 04/27/2017] [Accepted: 06/23/2017] [Indexed: 11/24/2022]
Abstract
BACKGROUND The federal Mental Health Parity and Addiction Equity Act (MHPAEA) sought to eliminate historical disparities between behavioral health and medical health insurance benefits among the commercially insured. This study determines whether MHPAEA was associated with increased BH expenditures and utilization among a population with substance use disorder (SUD) diagnoses. METHODS Claims and eligibility data from 5,987,776 enrollees, 2008-2013, were obtained from a national, commercial, managed behavioral health organization. An interrupted time series study design with segmented regression analysis estimated time trends of per-member-per-month (PMPM) spending and use before (2008-2009), during (2010), and after (2011-2013) MHPAEA compliance. The study sample contained individuals with drug or alcohol use disorder diagnosis during study period (N=2,716,473 member-month observations). Outcomes included: total, plan, patient out-of-pocket spending; outpatient utilization (assessment/diagnostic evaluation visits; medication management; individual, group and family psychotherapy, and structured outpatient care); intermediate care utilization (day treatment; recovery home and residential); and inpatient utilization. RESULTS Starting at the beginning of the post-parity period, MHPAEA was associated with increased levels of PMPM total and plan spending ($25.80 [p=0.01]; $28.33 [p=0.00], respectively), as well as the number of PMPM assessment/evaluation, individual psychotherapy, and group psychotherapy visits, and inpatient days (0.01 visits [p=0.01]; 0.02 visits [p=0.01]; 0.01 visits [p=0.03]; 0.01days [p=0.01], respectively). Following these initial level changes, MHPAEA was also associated with monthly increases in PMPM total, plan, and patent out-of-pocket spending ($2.56/month [p=0.00]; $2.25/month [p=0.00]; $0.27 [p=0.03], respectively), as well as structured outpatient visits and inpatient days (0.0012 visits/month [p=0.01]; 0.0012days/month [p=0.00]). CONCLUSION MHPAEA was associated with modest increases in total, plan, and patient out-of-pocket spending and outpatient and inpatient utilization. These increases, while modest in magnitude, are larger in magnitude than increases detected among a sample of all enrollees (i.e. not only those with SUD diagnoses).
Collapse
Affiliation(s)
- Sarah Friedman
- Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, 911 Broxton Avenue, Los Angeles, CA 90024, United States; Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, UCLA, 911 Broxton Avenue, Los Angeles, CA 90024, United States; School of Community Health Sciences, Division of Health Sciences, University of Nevada, 1664 N. Virginia Street, Reno, NV 89557, United States.
| | - Haiyong Xu
- Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, UCLA, 911 Broxton Avenue, Los Angeles, CA 90024, United States.
| | - Jessica M Harwood
- Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, UCLA, 10940 Wilshire Boulevard, Suite 700, Los Angeles, CA 90024, United States.
| | - Francisca Azocar
- Optum®, United Health Group, 425 Market Street, 14th Floor, San Francisco, CA 94105, United States.
| | - Brian Hurley
- Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, 50-078 Center for Health Sciences, Box 951683, Los Angeles, CA 90095, United States.
| | - Susan L Ettner
- Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, 911 Broxton Avenue, Los Angeles, CA 90024, United States; Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, UCLA, 911 Broxton Avenue, Los Angeles, CA 90024, United States.
| |
Collapse
|
2
|
Merrick EL, Horgan CM, Garnick DW, Reif S, Stewart MT. Accessing specialty behavioral health treatment in private health plans. J Behav Health Serv Res 2009; 36:420-35. [PMID: 19104944 PMCID: PMC4364135 DOI: 10.1007/s11414-008-9161-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2007] [Accepted: 11/19/2008] [Indexed: 11/24/2022]
Abstract
Connecting people to mental health and substance abuse services is critical, given the extent of unmet need. The way health plans structure access to care can play a role. This study examined treatment entry procedures for specialty behavioral health care in private health plans and their relationship with behavioral health contracting arrangements, focusing primarily on initial entry into outpatient treatment. The data source was a nationally representative health plan survey on behavioral health services in 2003 (N = 368 plans with 767 managed care products; 83% response rate). Most health plan products initially authorized six or more outpatient visits if authorization was required, did not routinely conduct telephonic clinical assessment, had standards for timely access, and monitored wait time. Products with carve-outs differed on several treatment entry dimensions. Findings suggest that health plans focus on timely access and typically do not heavily manage initial entry into outpatient treatment.
Collapse
Affiliation(s)
- Elizabeth L Merrick
- Heller School for Social Policy and Management, Brandeis University, Waltham, MA 02454-9110, USA.
| | | | | | | | | |
Collapse
|
3
|
Hodgkin D, Horgan CM, Garnick DW, Merrick EL. Benefit limits for behavioral health care in private health plans. ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH 2009; 36:15-23. [PMID: 19037721 PMCID: PMC2644559 DOI: 10.1007/s10488-008-0196-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2008] [Accepted: 11/03/2008] [Indexed: 10/21/2022]
Abstract
Data from a nationally representative sample of private health plans reveal that special lifetime limits on behavioral health care are rare (used by 16% of products). However, most plans have special annual limits on behavioral health utilization; for example, 90% limit outpatient mental health and 93% limit outpatient substance abuse treatment. As a result, enrollees in the average plan face substantial out-of-pocket costs for long-lasting treatment: a median of $2,710 for 50 mental health visits, or $2,400 for 50 substance abuse visits. Plans' access to new managed care tools has not led them to stop using benefit limits for cost containment purposes.
Collapse
Affiliation(s)
- Dominic Hodgkin
- Schneider Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, Waltham, MA 02454-9110, USA.
| | | | | | | |
Collapse
|